Assembly Biosciences Doses First Two Participants in Phase 2 ABI-6250 Study
Assembly Biosciences said it dosed the first two participants in a Phase 2 study of oral NTCP inhibitor ABI-6250 for chronic hepatitis delta virus.
Related stories
Duffy Says US Air Travel Disruption Will End by Tomorrow
Transportation Secretary Sean Duffy told NBC the disruption would be over by the end of today or tomorrow.
L impact | EQUITY | Nov 15, 2026, 02:24 PM UTC
US Air Travel Disruption Expected to End by Tomorrow, Duffy Says
Transportation Secretary Sean Duffy told NBC the US air travel disruption will be over by the end of today or tomorrow.
L impact | EQUITY | Nov 15, 2026, 02:05 PM UTC
Transportation Secretary Duffy Says US Air Travel Disruption Will End Soon
Duffy told NBC the disruption would be over by “end of today, end of tomorrow.”
L impact | EQUITY | Nov 15, 2026, 02:05 PM UTC
ESS Tech Files for Chapter 7 Bankruptcy and Ceases Operations
ESS Tech filed for Chapter 7 bankruptcy and terminated all employees and officers without cause. The iron flow battery company said it took the action after considering available s
M impact | EQUITY | Nov 15, 2026, 02:04 PM UTC
BMW Recalls 720,796 US Vehicles Over Potential Fire Risk
The recall affects several BMW models manufactured between 2012 and 2018. Safety regulators are asking owners to park affected vehicles outside and away from buildings until the pr
M impact | EQUITY | Nov 15, 2026, 02:03 PM UTC
Cardinal Infrastructure Posts Q3 Loss, Withdraws Guidance and Delays Acquisition
Cardinal Infrastructure reported a statutory third-quarter loss of US$0.21 per share and US$202 million in revenue, which was 14% below forecasts. EBITDA margin fell to 4.2%; the c
M impact | EQUITY | Nov 15, 2026, 02:03 PM UTC